Skip to content

Pharminent

cropped-banner_frontpage_2026-07-11-2.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut
  • M&A / Deals

BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut

BioSpace

Leading Beeline Medicines' pipeline is afimetoran, which is in Phase 2 development for systemic lupus erythematosus with data expected later this year.

M&A / DealsImmunology & InflammationRead full story

pharminent April 15, 2026

BioSpace

Leading Beeline Medicines’ pipeline is afimetoran, which is in Phase 2 development for systemic lupus erythematosus with data expected later this year.

M&A / DealsImmunology & InflammationRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Whitepaper: CDMOs at a Crossroads
Next: Daiichi exits OTC, with $1.55bn unit sale to Suntory

Related Stories

  • M&A / Deals

Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar

pharminent July 10, 2026
  • M&A / Deals

GSK ends dementia alliance with Alector after setbacks

pharminent July 9, 2026
  • M&A / Deals

AstraZeneca, GSK intensify China ties with Sino Biopharm deals

pharminent July 8, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.